Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the blad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet Oncology 2015-01, Vol.16 (1), p.76-86
Hauptverfasser: Sternberg, Cora N, Skoneczna, Iwona, Kerst, J. Martijn, Albers, Peter, Fossa, Sophie D, Agerbaek, Mads, Dumez, Herlinde, de Santis, Maria, Théodore, Christine, Leahy, Michael G, Chester, John D, Verbaeys, Antony, Daugaard, Gedske, Wood, Lori, Witjes, J. Alfred, de Wit, Ronald, Geoffrois, Lionel, Sengelov, Lisa, Thalmann, George, Charpentier, Danielle, Rolland, Frédéric, Mignot, Laurent, Sundar, Santhanam, Symonds, Paul, Graham, John, Joly, Florence, Marreaud, Sandrine, Collette, Laurence, Sylvester, Richard, European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group, Groupe d'Etude des Tumeurs Urogénitales, National Cancer Research Institute Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, German Association of Urologic Oncology
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder.
ISSN:1470-2045